Praxis Precision Medicines
Clinical trials sponsored by Praxis Precision Medicines, explained in plain language.
-
New hope for kids with hard-to-treat genetic seizures
Disease control OngoingThis study tests a new medicine called PRAX-562 in 77 children with rare genetic epilepsies (SCN2A or SCN8A). The goal is to see if it safely reduces motor seizures. The trial has two parts: a double-blind phase where some children get the drug and some get a placebo, followed by…
Phase: PHASE2, PHASE3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New epilepsy drug vormatrigine tested for Long-Term safety in 700 adults
Disease control ENROLLING_BY_INVITATIONThis study is testing the long-term safety of a once-daily drug called vormatrigine in 700 adults with focal or generalized tonic-clonic seizures. Participants must have already taken vormatrigine in a previous trial or program. The main goal is to check for side effects and chan…
Phase: PHASE3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New pill aims to steady shaking hands in essential tremor trial
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a new drug called ulixacaltamide can safely reduce tremors and improve daily activities in adults with essential tremor. About 1,000 participants will receive either the drug or a placebo for up to 12 weeks, then may join a long-term safety study. The goa…
Phase: PHASE3 • Sponsor: Praxis Precision Medicines • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC